AbbVie Net Receivables vs Non Current Liabilities Total Analysis
ABBV Stock | USD 182.93 0.15 0.08% |
AbbVie financial indicator trend analysis is way more than just evaluating AbbVie Inc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AbbVie Inc is a good investment. Please check the relationship between AbbVie Net Receivables and its Non Current Liabilities Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Net Receivables vs Non Current Liabilities Total
Net Receivables vs Non Current Liabilities Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AbbVie Inc Net Receivables account and Non Current Liabilities Total. At this time, the significance of the direction appears to have very strong relationship.
The correlation between AbbVie's Net Receivables and Non Current Liabilities Total is 0.85. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of AbbVie Inc, assuming nothing else is changed. The correlation between historical values of AbbVie's Net Receivables and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of AbbVie Inc are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Net Receivables i.e., AbbVie's Net Receivables and Non Current Liabilities Total go up and down completely randomly.
Correlation Coefficient | 0.85 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Net Receivables
Non Current Liabilities Total
Most indicators from AbbVie's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AbbVie Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Sales General And Administrative To Revenue is likely to climb to 0.28 in 2024, whereas Selling General Administrative is likely to drop slightly above 7.8 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 38.8B | 40.6B | 33.9B | 24.3B | Total Revenue | 56.2B | 58.1B | 54.3B | 33.8B |
AbbVie fundamental ratios Correlations
Click cells to compare fundamentals
AbbVie Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AbbVie fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 1.5B | 1.7B | 1.8B | 1.8B | 1.8B | 1.8B | |
Total Assets | 89.1B | 150.6B | 146.5B | 138.8B | 134.7B | 81.2B | |
Other Current Liab | 10.4B | 17.9B | 19.8B | 22.5B | 27.0B | 28.3B | |
Total Current Liabilities | 15.6B | 28.7B | 35.2B | 29.5B | 37.8B | 39.7B | |
Total Stockholder Equity | (8.2B) | 13.1B | 15.4B | 17.3B | 10.4B | 7.1B | |
Other Liab | 18.5B | 30.4B | 31.0B | 31.7B | 36.5B | 38.3B | |
Property Plant And Equipment Net | 3.0B | 5.2B | 5.1B | 4.9B | 5.0B | 3.6B | |
Net Debt | 26.8B | 77.6B | 66.9B | 54.1B | 46.6B | 32.2B | |
Accounts Payable | 1.5B | 2.3B | 2.9B | 2.9B | 3.7B | 3.9B | |
Cash | 39.9B | 8.4B | 9.7B | 9.2B | 12.8B | 10.5B | |
Non Current Assets Total | 39.6B | 126.4B | 118.6B | 110.3B | 101.7B | 57.7B | |
Other Assets | 1.9B | 5.1B | 4.1B | 4.8B | 5.6B | 5.8B | |
Cash And Short Term Investments | 39.9B | 8.5B | 9.8B | 9.2B | 12.8B | 11.0B | |
Net Receivables | 5.4B | 8.8B | 10.0B | 11.3B | 11.2B | 6.8B | |
Good Will | 15.6B | 33.1B | 32.4B | 32.2B | 32.3B | 18.6B | |
Short Term Investments | 0.0 | 30M | 84M | 28M | 2M | 1.9M | |
Liabilities And Stockholders Equity | 89.1B | 150.6B | 146.5B | 138.8B | 134.7B | 81.2B | |
Non Current Liabilities Total | 81.7B | 108.8B | 95.9B | 92.0B | 86.5B | 55.5B | |
Inventory | 1.8B | 3.3B | 3.1B | 3.6B | 4.1B | 2.2B | |
Other Stockholder Equity | (9.3B) | 15.1B | 15.2B | 14.7B | 13.6B | 7.1B | |
Total Liab | 97.3B | 137.5B | 131.1B | 121.5B | 124.3B | 74.1B | |
Property Plant And Equipment Gross | 3.0B | 5.2B | 10.7B | 11.0B | 11.6B | 12.2B | |
Total Current Assets | 49.5B | 24.2B | 27.9B | 28.5B | 33.0B | 23.5B | |
Accumulated Other Comprehensive Income | (3.6B) | (3.1B) | (2.9B) | (2.2B) | (2.3B) | (2.4B) | |
Intangible Assets | 18.6B | 82.9B | 76.0B | 67.4B | 55.6B | 32.2B | |
Property Plant Equipment | 3.0B | 5.2B | 5.1B | 4.9B | 5.7B | 3.4B | |
Long Term Debt | 63.0B | 77.6B | 64.2B | 59.1B | 52.2B | 41.2B | |
Short Long Term Debt Total | 66.7B | 86.1B | 76.7B | 63.3B | 59.4B | 49.8B | |
Non Currrent Assets Other | 1.2B | 4.9B | 4.9B | 5.6B | 8.5B | 8.9B | |
Short Term Debt | 3.8B | 8.5B | 12.5B | 4.1B | 7.2B | 5.2B | |
Net Tangible Assets | (42.4B) | (102.9B) | (96.2B) | (82.3B) | (74.1B) | (77.8B) | |
Retained Earnings | 4.7B | 1.1B | 3.1B | 4.8B | (1B) | (950M) | |
Retained Earnings Total Equity | 4.7B | 1.1B | 3.1B | 4.8B | 5.5B | 3.4B | |
Long Term Debt Total | 63.0B | 77.6B | 64.2B | 59.1B | 68.0B | 50.1B | |
Capital Surpluse | 15.2B | 17.4B | 18.3B | 19.2B | 22.1B | 15.8B | |
Additional Paid In Capital | 15.2B | 17.4B | 18.3B | 19.2B | 20.2B | 15.0B |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for AbbVie Stock Analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.